Chongqing, China – September 8, 2025 — The 2025 World Intelligence Expo, jointly hosted by the Chongqing Municipal People’s Government and the Tianjin Municipal People’s Government, was grandly held at the Chongqing International Expo Center from September 4 to 8. The event brought together global technology leaders and industry elites to explore the latest trends in smart innovation.

As a global leader in focused ultrasound technology, Chongqing HAIFU Medical Technology Co., Ltd. (hereinafter “HAIFU ”) was invited to participate, showcasing its series of non-invasive treatment systems including the HAIFU® Focused Ultrasound Tumor Therapeutic System and Seapostar. The company’s booth drew significant attention, offering visitors an immersive experience of China’s original “medical black technology” and its frontier applications in intelligent healthcare.

Bringing Smart, Non-invasive Medicine to the World

The HAIFU Medical exhibition area was bustling with visitors, featuring dedicated zones for product displays, technical presentations, and hands-on interactive experiences. Guests enthusiastically tried the company’s focused ultrasound joint massager, while experts demonstrated the technology’s innovative clinical applications through live simulations, detailed explanations, and educational videos. These presentations offered a clear view of how focused ultrasound can be applied not only in non-invasive surgery but also in rehabilitation and daily healthcare.

At the heart of HAIFU ’s technology is its flagship device—the HAIFU® Knife, China’s first large-scale therapeutic system with fully independent intellectual property rights. With self-developed core technologies and key components, the device is recognized at the forefront of global innovation. Using High-Intensity Focused Ultrasound (HIFU) ablation, it enables treatment of solid tumors—including liver, pancreatic, breast, and uterine cancers, as well as benign diseases such as fibroids and adenomyosis—without incisions, bleeding, or radiation while preserving organ integrity.

For elderly or frail patients who cannot undergo surgery, and for women with reproductive needs, this non-invasive procedure offers a unique advantage: patients can typically prepare for pregnancy within 3–6 months after HIFU ablation. The therapy involves no trauma, allows discharge the next day, and results in significantly lower overall treatment costs.

Global Reach and Medical Impact

To date, HAIFU® systems have been exported to 35 countries and regions, treating more than 330,000 patients worldwide. The company’s equipment has been installed in over 3,000 medical institutions across China and in more than 80 hospitals abroad, particularly along the Belt and Road regions—accounting for one-third of the world’s focused ultrasound therapy systems.

One of the distinct advantages of focused ultrasound surgery is its short learning curve. Traditional open surgeries require years of skill refinement, while HIFU systems incorporate intelligent navigation and targeting technologies that allow doctors to master the procedure quickly through structured theoretical courses and hands-on simulation.

HAIFU Medical provides comprehensive training programs combining lectures, case studies, and on-site guidance to help clinicians rapidly gain proficiency. This not only enhances clinical efficiency but also helps hospitals address the shortage of skilled surgical professionals. Moreover, since HIFU treatments can be performed while seated and in a stress-free environment, the technology reduces physical strain on doctors and extends their professional longevity.

Driving the Future of Smart Medicine

In an era defined by intelligent innovation, HAIFU Medical continues to energize the healthcare industry with pioneering medical technologies and solutions. The global expansion of focused ultrasound therapy represents a powerful step toward a future where precision, safety, and compassion define medical care — bringing health and hope to patients around the world.